InnoChem-25 Conference

I am happy to contribute to this fascinating upcoming event!

Join the International Conference on Recent Breakthroughs in Chemical Sciences (InnoChem-25) organized by the School of Sciences, Woxsen University.

🔬 Theme: Innovations in Chemistry for Sustainable Solutions

📅 April 8-11, 2025
🌐 Fully Online Conference

Featuring distinguished plenary speakers:
– Dr. Joe Wang (University of California San Diego, USA)
– Prof. Kara Bren (University of Rochester, USA)
– Dr. Tamas Sohajda (CarboHyde, Hungary)
– Dr. Tapas Sen, PhD, FRSC, FHEA, FRSM (University of Central Lancashire, UK)

Plus an impressive lineup of keynote speakers from renowned institutions worldwide, including experts from ICT Mumbai, IIT Hyderabad, Czech Republic, Nigeria, and more!

Perfect opportunity for:
• Chemical scientists
• Researchers
• Industry professionals
• Academia

Register now: REGISTRATION FEE ONLINE

Cyclodextrin Tales: Celebrating 100 Issues

Actually, it’s 103 already.

I started writing this newsletter on the 23rd January, 2023.

In the ever-evolving world of science, staying updated on the latest research of cyclodextrins can be a challenge. Cyclodextrin Tales, a LinkedIn-based scientific newsletter, has been bridging that gap by providing insightful articles on cyclodextrins—fascinating ring-shaped molecules with applications in pharmaceuticals, food, and beyond. Now, with its 100th issue, the blog has firmly established itself as a go-to resource for scientists, researchers, and industry professionals alike.

Launched to bring awareness and discussion around cyclodextrins, Cyclodextrin Tales has consistently delivered high-quality, engaging content. Each issue dives into a different aspect of these versatile molecules, from their role in drug delivery and environmental applications to emerging innovations in material science. The blog’s ability to break down complex scientific concepts into accessible insights has made it an essential read for both experts and newcomers to the field.

If you like these brief communications, Subscribe to join 4500 cyclodextrin enthusiasts, and gain and share knowledge on current and novel applications, challenges, and possibilities.

Beyond just being informative, Cyclodextrin Tales has cultivated a growing community of professionals who share a passion for these intriguing molecules, counting now 4500+ subscribers. Discussions sparked by each issue have led to collaborations, knowledge exchange, and deeper engagement within the scientific world. By reaching this 100th issue milestone, the blog not only marks a numerical achievement but also highlights the sustained curiosity and innovation surrounding cyclodextrins.

As Cyclodextrin Tales looks ahead to the future, it remains a valuable hub for scientific exploration. With new research constantly emerging, the blog is set to continue its mission of educating, inspiring, and connecting people in the world of cyclodextrins. Here’s to the next 100 issues and beyond!

Some of my favorite issues?

Size Matters: How Cyclodextrin Cavity Size Impacts its Applications

CarboHydrate Chronicles – the podcast to meet cyclodextrin experts

Exploring the Visionary Role: Ophthalmic Uses of Cyclodextrins

Beyond the Doughnut: Cyclodextrins as Nanoparticles in Cutting-Edge Innovations

The Story Behind Sugammadex’s Success

CarboHyde Cyclodextrin Masterclass IV

What to Expect?
Explore the evolving landscape of cyclodextrin-based drug delivery, from established uses to groundbreaking innovations. Our expert speaker will dissect key advancements, addressing both challenges and transformative opportunities that enhance therapeutic efficacy.

Key Focus Areas:
Monoclonal Antibodies
Gene Therapy
Vaccines
Biotechnology

You can register here: Cyclodextrin Masterclass IV – CarboHyde

Today, we became 3 years old

So officially nursery is over, we are almost fully grown now and can start kindergarten.

No more diapers needed and we can use the scissors too.

We ae sincerely grateful for all the support we received during our first years from partners, collaborators, friends and colleagues. Without you, creating this workshop of cyclodextrin innovation would not have been possible.

so THANK YOU!

And feel free to serve yourself from the cake. When in Budapest, step by and be our guest.

Kristóf Felegyi PhD defense

What a bright day for our company!

We have a new PhD among us, huge congratulations to Kristóf Felegyi (and maybe his wife, Csenge Anna Felegyi-Tóth :P) to a successful defense!

Summary of the PhD thesis:

The dissertation investigates the chemical composition and biological activities of Buglossoporus quercinus and Xylobolus subpileatus.

  • B. quercinus: Identified novel and known polyporenic acids. Some compounds showed moderate antiproliferative effects on colon cancer cells and inhibited the P-glycoprotein efflux pump. Synergistic interactions with doxorubicin were observed.
  • X. subpileatus: Isolated seven compounds, including a new natural product (XB-1). Some metabolites exhibited enzyme inhibition, with XB-3 showing strong antityrosinase activity and XB-3/4 inhibiting AChE and BChE.

The findings suggest potential applications in cancer treatment and enzyme inhibition.

Also this means that now 50+% of our fantastic team has PhD! Not bad…

CarboHyde at University of Szeged

Just when you thought you knew everyting about cyclodextrins…

It could be a fascinating Hollywood movie title, yet now, this is the keynote Balázs Attila Kondoros delivered this morning at a conference (Symposium of Young Researcher on Pharmaceutical Technology, Biotechnology and Regulatory Science) for young formulation scientists at University of Szeged.

Later Tamas Kiss, PhD was chairing a session too, so our team members got important roles today.

Also, the conference, features almost 10 presentations about cyclodextrin applications. Such active research in the area is both heartwarming and reassuring.

Daniel Bisericaru received the “Egis Kiválósági Ösztöndíj” award

We just received word that Daniel Bisericaru, a bright, young member of our med-chem team, has been awarded the “Egis kiválósági ösztöndíj” – which is a one-year scholarship for PhD students by Egis Pharmaceuticals PLC.

Dani’s core project is the development of amino-acid conjugated cyclodextrins that we are evaluating both as drug delivery vehicles and active ingredients in several biological models.

We are proud of your success Dani and happy to have you with us!

Daniel Bisericaru, CarboHyde